Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation

Nigel J. Pyne, Melissa McNaughton, Stephanie Boomkamp, Neil MacRitchie, Cecilia Evangelisti, Alberto M. Martelli, Hui-Rong Jiang, Satvir Kaur Ubhi, Susan Pyne

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Sphingosine kinase (there are two isoforms, SK1 and SK2) catalyses the formation of sphingosine 1-phosphate (S1P), a bioactive lipid that can be released from cells to activate a family of G protein-coupled receptors, termed S1P1-5. In addition, S1P can bind to intracellular target proteins, such as HDAC1/2, to induce cell responses. There is increasing evidence of a role for S1P receptors (e.g. S1P4) and SK1 in cancer, where high expression of these proteins in ER negative breast cancer patient tumours is linked with poor prognosis. Indeed, evidence will be presented here to demonstrate that S1P4 is functionally linked with SK1 and the oncogene HER2 (ErbB2) to regulate mitogen-activated protein kinase pathways and growth of breast cancer cells. Although much emphasis is placed on SK1 in terms of involvement in oncogenesis, evidence will also be presented for a role of SK2 in both T-cell and B-cell acute lymphoblastic leukemia. In patient T-ALL lymphoblasts and T-ALL cell lines, we have demonstrated that SK2 inhibitors promote T-ALL cell death via autophagy and induce suppression of c-myc and PI3K/AKT pathways. We will also present evidence demonstrating that certain SK inhibitors promote oxidative stress and protein turnover via proteasomal degradative pathways linked with induction of p53-and p21-induced growth arrest. In addition, the SK1 inhibitor, PF-543 exacerbates disease progression in an experimental autoimmune encephalomyelitis mouse model indicating that SK1 functions in an anti-inflammatory manner. Indeed, sphingosine, which accumulates upon inhibition of SK1 activity, and sphingosine-like compounds promote activation of the inflammasome, which is linked with multiple sclerosis, to stimulate formation of the pro-inflammatory mediator, IL-1β. Such compounds could be exploited to produce antagonists that diminish exaggerated inflammation in disease. The therapeutic potential of modifying the SK-S1P receptor pathway in cancer and inflammation will therefore, be reviewed.
LanguageEnglish
Pages151-159
Number of pages9
JournalAdvances in Biological Regulation
Volume60
Early online date25 Sep 2015
DOIs
Publication statusPublished - 1 Jan 2016

Fingerprint

Lysosphingolipid Receptors
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Sphingosine
Inflammation
Breast Neoplasms
Inflammasomes
Neoplasms
Autoimmune Experimental Encephalomyelitis
Autophagy
Growth
G-Protein-Coupled Receptors
Heat-Shock Proteins
Mitogen-Activated Protein Kinases
Phosphatidylinositol 3-Kinases
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Oncogenes
Multiple Sclerosis
Disease Progression
Protein Isoforms
Carcinogenesis

Keywords

  • sphingosine kinase
  • G protein coupled receptors (GPCR)
  • SK1
  • SK2
  • breast cancer
  • cancer cells

Cite this

Pyne, Nigel J. ; McNaughton, Melissa ; Boomkamp, Stephanie ; MacRitchie, Neil ; Evangelisti, Cecilia ; Martelli, Alberto M. ; Jiang, Hui-Rong ; Ubhi, Satvir Kaur ; Pyne, Susan. / Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation. In: Advances in Biological Regulation. 2016 ; Vol. 60. pp. 151-159.
@article{a84c48efb71f445eb0a327fab6066c8f,
title = "Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation",
abstract = "Sphingosine kinase (there are two isoforms, SK1 and SK2) catalyses the formation of sphingosine 1-phosphate (S1P), a bioactive lipid that can be released from cells to activate a family of G protein-coupled receptors, termed S1P1-5. In addition, S1P can bind to intracellular target proteins, such as HDAC1/2, to induce cell responses. There is increasing evidence of a role for S1P receptors (e.g. S1P4) and SK1 in cancer, where high expression of these proteins in ER negative breast cancer patient tumours is linked with poor prognosis. Indeed, evidence will be presented here to demonstrate that S1P4 is functionally linked with SK1 and the oncogene HER2 (ErbB2) to regulate mitogen-activated protein kinase pathways and growth of breast cancer cells. Although much emphasis is placed on SK1 in terms of involvement in oncogenesis, evidence will also be presented for a role of SK2 in both T-cell and B-cell acute lymphoblastic leukemia. In patient T-ALL lymphoblasts and T-ALL cell lines, we have demonstrated that SK2 inhibitors promote T-ALL cell death via autophagy and induce suppression of c-myc and PI3K/AKT pathways. We will also present evidence demonstrating that certain SK inhibitors promote oxidative stress and protein turnover via proteasomal degradative pathways linked with induction of p53-and p21-induced growth arrest. In addition, the SK1 inhibitor, PF-543 exacerbates disease progression in an experimental autoimmune encephalomyelitis mouse model indicating that SK1 functions in an anti-inflammatory manner. Indeed, sphingosine, which accumulates upon inhibition of SK1 activity, and sphingosine-like compounds promote activation of the inflammasome, which is linked with multiple sclerosis, to stimulate formation of the pro-inflammatory mediator, IL-1β. Such compounds could be exploited to produce antagonists that diminish exaggerated inflammation in disease. The therapeutic potential of modifying the SK-S1P receptor pathway in cancer and inflammation will therefore, be reviewed.",
keywords = "sphingosine kinase, G protein coupled receptors (GPCR), SK1, SK2, breast cancer, cancer cells",
author = "Pyne, {Nigel J.} and Melissa McNaughton and Stephanie Boomkamp and Neil MacRitchie and Cecilia Evangelisti and Martelli, {Alberto M.} and Hui-Rong Jiang and Ubhi, {Satvir Kaur} and Susan Pyne",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.jbior.2015.09.001",
language = "English",
volume = "60",
pages = "151--159",
journal = "Advances in Biological Regulation",
issn = "2212-4934",
publisher = "Elsevier BV",

}

Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation. / Pyne, Nigel J.; McNaughton, Melissa; Boomkamp, Stephanie; MacRitchie, Neil; Evangelisti, Cecilia; Martelli, Alberto M.; Jiang, Hui-Rong; Ubhi, Satvir Kaur; Pyne, Susan.

In: Advances in Biological Regulation, Vol. 60, 01.01.2016, p. 151-159.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation

AU - Pyne, Nigel J.

AU - McNaughton, Melissa

AU - Boomkamp, Stephanie

AU - MacRitchie, Neil

AU - Evangelisti, Cecilia

AU - Martelli, Alberto M.

AU - Jiang, Hui-Rong

AU - Ubhi, Satvir Kaur

AU - Pyne, Susan

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Sphingosine kinase (there are two isoforms, SK1 and SK2) catalyses the formation of sphingosine 1-phosphate (S1P), a bioactive lipid that can be released from cells to activate a family of G protein-coupled receptors, termed S1P1-5. In addition, S1P can bind to intracellular target proteins, such as HDAC1/2, to induce cell responses. There is increasing evidence of a role for S1P receptors (e.g. S1P4) and SK1 in cancer, where high expression of these proteins in ER negative breast cancer patient tumours is linked with poor prognosis. Indeed, evidence will be presented here to demonstrate that S1P4 is functionally linked with SK1 and the oncogene HER2 (ErbB2) to regulate mitogen-activated protein kinase pathways and growth of breast cancer cells. Although much emphasis is placed on SK1 in terms of involvement in oncogenesis, evidence will also be presented for a role of SK2 in both T-cell and B-cell acute lymphoblastic leukemia. In patient T-ALL lymphoblasts and T-ALL cell lines, we have demonstrated that SK2 inhibitors promote T-ALL cell death via autophagy and induce suppression of c-myc and PI3K/AKT pathways. We will also present evidence demonstrating that certain SK inhibitors promote oxidative stress and protein turnover via proteasomal degradative pathways linked with induction of p53-and p21-induced growth arrest. In addition, the SK1 inhibitor, PF-543 exacerbates disease progression in an experimental autoimmune encephalomyelitis mouse model indicating that SK1 functions in an anti-inflammatory manner. Indeed, sphingosine, which accumulates upon inhibition of SK1 activity, and sphingosine-like compounds promote activation of the inflammasome, which is linked with multiple sclerosis, to stimulate formation of the pro-inflammatory mediator, IL-1β. Such compounds could be exploited to produce antagonists that diminish exaggerated inflammation in disease. The therapeutic potential of modifying the SK-S1P receptor pathway in cancer and inflammation will therefore, be reviewed.

AB - Sphingosine kinase (there are two isoforms, SK1 and SK2) catalyses the formation of sphingosine 1-phosphate (S1P), a bioactive lipid that can be released from cells to activate a family of G protein-coupled receptors, termed S1P1-5. In addition, S1P can bind to intracellular target proteins, such as HDAC1/2, to induce cell responses. There is increasing evidence of a role for S1P receptors (e.g. S1P4) and SK1 in cancer, where high expression of these proteins in ER negative breast cancer patient tumours is linked with poor prognosis. Indeed, evidence will be presented here to demonstrate that S1P4 is functionally linked with SK1 and the oncogene HER2 (ErbB2) to regulate mitogen-activated protein kinase pathways and growth of breast cancer cells. Although much emphasis is placed on SK1 in terms of involvement in oncogenesis, evidence will also be presented for a role of SK2 in both T-cell and B-cell acute lymphoblastic leukemia. In patient T-ALL lymphoblasts and T-ALL cell lines, we have demonstrated that SK2 inhibitors promote T-ALL cell death via autophagy and induce suppression of c-myc and PI3K/AKT pathways. We will also present evidence demonstrating that certain SK inhibitors promote oxidative stress and protein turnover via proteasomal degradative pathways linked with induction of p53-and p21-induced growth arrest. In addition, the SK1 inhibitor, PF-543 exacerbates disease progression in an experimental autoimmune encephalomyelitis mouse model indicating that SK1 functions in an anti-inflammatory manner. Indeed, sphingosine, which accumulates upon inhibition of SK1 activity, and sphingosine-like compounds promote activation of the inflammasome, which is linked with multiple sclerosis, to stimulate formation of the pro-inflammatory mediator, IL-1β. Such compounds could be exploited to produce antagonists that diminish exaggerated inflammation in disease. The therapeutic potential of modifying the SK-S1P receptor pathway in cancer and inflammation will therefore, be reviewed.

KW - sphingosine kinase

KW - G protein coupled receptors (GPCR)

KW - SK1

KW - SK2

KW - breast cancer

KW - cancer cells

UR - http://www.ncbi.nlm.nih.gov/pubmed/26429117

UR - http://www.sciencedirect.com/science/article/pii/S2212492615300075

U2 - 10.1016/j.jbior.2015.09.001

DO - 10.1016/j.jbior.2015.09.001

M3 - Article

VL - 60

SP - 151

EP - 159

JO - Advances in Biological Regulation

T2 - Advances in Biological Regulation

JF - Advances in Biological Regulation

SN - 2212-4934

ER -